12/18/2023 |
CBER 2023 Orphan Approvals (new BLAs) |
12/18/2023 |
CBER Vacancy: Staff Fellows – Chemistry Manufacturing and Controls (CMC) Review Scientists |
12/15/2023 |
December 15, 2023 Approval Letter - ALYGLO |
12/15/2023 |
SOPP 8001.4: Review of Proprietary Names for CBER Regulated Products |
12/15/2023 |
SOPP 8301: Receipt and Processing of Master Files |
12/15/2023 |
CBER Rare Disease Program Announcements |
12/15/2023 |
CBER Title 21 Vacancy Announcement - Management Analyst, AD-0343-Band A/B, Office of Management (OM), Division of Human Capital (DHC), Management Services Branch (MSB) |
12/14/2023 |
Standards Development for Regenerative Medicine Therapies
Updated |
12/14/2023 |
CBER Title 21 Vacancy Announcement – Biologist (Senior Advisor), AD-0401-Band D, Office of Regulatory Operations (ORO), Division of Regulatory Operations and Programs (DROP), Regulatory Programs Branch (RPB) |
12/13/2023 |
Statistical Review - BIVIGAM |
12/13/2023 |
Clinical Review Memo - BIVIGAM |
12/13/2023 |
BK231015 - Reveal G4 Rapid HIV-1/2 Antibody Test |
12/13/2023 |
Advanced Manufacturing Technologies Designation Program; Draft Guidance for Industry |
12/13/2023 |
eSubmitter Application History |
12/12/2003 |
CBER 2023 Orphan Approvals (new BLAs) |
12/12/2023 |
December 11, 2023 Approval Letter - TECARTUS |
12/12/2023 |
December 8, 2023 Summary Basis for Regulatory Action - IXCHIQ |
12/12/2023 |
December 11, 2023 Approval Letter - Wilate |
12/12/2023 |
CBER Title 21 Vacancy Announcement – Branch Chief, Band D, Office of Regulatory Operations (ORO), Division of Information Technology (DIT), Program Management and Analysis Branch (PMAB) |
12/11/2023 |
Clinical Pharmacology Review - Wilate |
12/11/2023 |
Statistical Review - Wilate |
12/11/2023 |
December 8, 2023 Approval Letter - BIVIGAM |
12/11/2023 |
CBER Title 21 Vacancy Announcement - Division Director, AD-Band F, Office of Vaccines Research and Review (OVRR), Division of Review Management and Regulatory Review (DRMRR) |
12/8/2023 |
Verification Systems Under the Drug Supply Chain Security Act for Certain Prescription Drugs; Guidance for Industry |
12/8/2023 |
December 8, 2023 Approval Letter - CASGEVY |
12/8/2023 |
December 8, 2023 Approval Letter - LYFGENIA |
12/6/2023 |
CBER Cures Vacancy Announcement - Physician (Hematology/Oncology) AD-0602-Band C, Office of Therapeutic Products (OTP), Office of Clinical Evaluation (OCE) |
12/4/2023 |
December 1, 2023 Approval Letter - Wilate |
12/01/2023 |
December 1, 2023 Approval Letter - ODACTRA |
11/30/2023 |
November 9, 2023 Summary Basis for Regulatory Action - ADZYNMA |
11/30/2023 |
November 29, 2023 Approval Letter - Fluzone |
11/29/2023 |
COVID-19: Developing Drugs and Biological Products for Treatment or Prevention; Guidance for Industry |
11/29/2023 |
Warrior Families: Advancing Regenerative Medicine Through Science Webinar Transcript |
11/29/2023 |
Warrior Families: Advancing Regenerative Medicine Through Science Presentation Slides |
11/28/2023 |
Translation of Good Laboratory Practice Study Reports: Questions and Answers; Draft Guidance for Industry |
11/28/2023 |
BK231004- Blood Product Questionnaire Module |
11/28/2023 |
FDA Investigating Serious Risk of T-cell Malignancy Following BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies |
11/27/2023 |
Voluntary Consensus Standards Recognition Program for Regenerative Medicine Therapies; Guidance for Industry
(Updated November 27, 2023) |
11/27/2023 |
November 17, 2023 Summary Basis for Regulatory Action - PENBRAYA |
11/27/2023 |
SOPP 8101.1: Regulatory Meetings with Sponsors and Applicants for Drugs and Biological Products |
11/21/2023 |
CBER CURES Vacancy Announcement – Deputy Office Director, AD-Band F, Office of Vaccines Research and Review (OVRR), Immediate Office of the Director (IOD)
Updated closing date |
11/20/2023 |
Notifying FDA of a Permanent Discontinuance or Interruption in Manufacturing of a Device Under Section 506J of the FD&C Act; Guidance for Industry and Food and Drug Administration Staff |